NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection with SGLT2 Inhibitors

By João L. Carapinha

February 19, 2026

Type 2 Diabetes Guidelines Reshape Initial Treatment The latest Type 2 Diabetes Guidelines from NICE (National Institute for Health and Care Excellence), published on 18 February 2026 as an update to guideline NG28 ("Type 2 diabe...
Enhancing Safety and Performance: The Role of EU Medical Device Panels

By João L. Carapinha

EU Medical Device Panels: Enhancing Safety and Performance Evaluations EU Medical Device Panels established by the European Medicines Agency (EMA) provide specialized expertise on clinical and performance evaluat...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation

By João L. Carapinha

MFN Policy Effectiveness in Countering Freeloading Claims The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing b...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implications for Alzheimer&...

By HEOR Staff Writer

February 18, 2026

Dutch Health Insurance Rejects Lecanemab Coverage Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basic health insurance package, marking a key lecanema...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose

By João L. Carapinha

European Commission Backs Wegovy Obesity Treatment with 7.2 mg Dose The European Commission has approved a higher 7.2 mg maintenance dose of
Revised MenACWY Vaccination Strategy for Adolescents in Germany

By HEOR Staff Writer

G-BA Approves MenACWY Vaccination Strategy Shift for Adolescents Germany's Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) has approved key amendments to the Protective Vaccination Directive on December 18...
View All News
Search By Category

Syenza's Top Picks

CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals

2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solutions

WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults

Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft Annual Work Programme 2026

Preparing for the EU Health Technology Assessment: Key Insights from the Upcoming 2026 Webinar

EU Launches Joint Scientific Consultations to Enhance Health Technology Assessment

Medicare Drug Price Negotiations: Major Savings for Seniors on Cancer and Chronic Disease Medications by 2027

Latest

NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection with SGLT2 Inhibitors

By João L. Carapinha

February 19, 2026

Type 2 Diabetes Guidelines Reshape Initial Treatment The latest Type 2 Diabetes Guidelines from NICE (National Institute for Health and Care Excellence), published on 18 February 2026 as an update to guideline NG28 ("Type 2 diabe...

Latest

Enhancing Safety and Performance: The Role of EU Medical Device Panels

By João L. Carapinha

EU Medical Device Panels: Enhancing Safety and Performance Evaluations EU Medical Device Panels established by the European Medicines Agency (EMA) provide specialized expertise on clinical and performance evaluat...

Latest

Exploring MFN Policy Effectiveness in Drug Pricing and Innovation

By João L. Carapinha

MFN Policy Effectiveness in Countering Freeloading Claims The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing b...

Latest

Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implications for Alzheimer&...

By HEOR Staff Writer

February 18, 2026

Dutch Health Insurance Rejects Lecanemab Coverage Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basic health insurance package, marking a key lecanema...

Global Updates

NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection with SGLT2 Inhibitors

By João L. Carapinha

February 19, 2026

Type 2 Diabetes Guidelines Reshape Initial Treatment The latest Type 2 Diabetes Guidelines from NICE (National Institute for Health and Care Excellence), published on 18 February 2026 as an update to guideline NG28 ("Type 2 diabe...

Global Updates

Exploring MFN Policy Effectiveness in Drug Pricing and Innovation

By João L. Carapinha

MFN Policy Effectiveness in Countering Freeloading Claims The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing b...

Global Updates

Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision

By João L. Carapinha

February 13, 2026

Exposing Prescription Drug Pricing Flaws Prescription drug pricing in the US is riddled with inefficiencies, as revealed in this JAMA interview published online on Febru...

Global Updates

Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM

By João L. Carapinha

February 10, 2026

ConfiDx Ushers in Uncertainty-Aware Diagnostics Uncertainty-aware diagnostics are transforming clinical decision-making through ConfiDx, a large language model (LLM) trained to recognize diagnostic uncertainty in cases with limited cl...

Europe

View All
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection with SGLT2 Inhibitors

By João L. Carapinha

February 19, 2026

Type 2 Diabetes Guidelines Reshape Initial Treatment The latest Type 2 Diabetes Guidelines from NICE (National Institute for Health and Care Excellence), published on 18 February 2026 as an update to guideline NG28 ("Type 2 diabe...
Enhancing Safety and Performance: The Role of EU Medical Device Panels

By João L. Carapinha

EU Medical Device Panels: Enhancing Safety and Performance Evaluations EU Medical Device Panels established by the European Medicines Agency (EMA) provide specialized expertise on clinical and performance evaluat...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implications for Alzheimer&...

By HEOR Staff Writer

February 18, 2026

Dutch Health Insurance Rejects Lecanemab Coverage Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basic health insurance package, marking a key lecanema...
European Commission Approves Enhanced Wegovy Obesity Treatment Dose

By João L. Carapinha

European Commission Backs Wegovy Obesity Treatment with 7.2 mg Dose The European Commission has approved a higher 7.2 mg maintenance dose of

North America

View All
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation

By João L. Carapinha

February 19, 2026

MFN Policy Effectiveness in Countering Freeloading Claims The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing b...
Genotype ECG Prediction

By João L. Carapinha

February 17, 2026

Bridging Genotype ECG Prediction to Enhanced Cardiovascular Risk Assessment Genotype ECG prediction advancements, exemplified by the CapECG model, enable direct mapping of genetic data to electrocardiogram ...
Transformative PBM Reform Legislation Signed into Law

By João L. Carapinha

February 16, 2026

PBM Reform Legislation Signed into Law President Trump signed a comprehensive spending bill incorporating landmark PBM reform legislation, ending a partial government shutdown while targeting pharmacy benefit managers (PBMs) with transformativ...
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial

By HEOR Staff Writer

February 13, 2026

Breakthroughs in Bladder Cancer Treatments at ASCO GU Merck unveiled promising bladder cancer treatments at the 2026 ASCO Genitourinary (GU) Cancers Symposium, showcasing data from its portfolio including KEYTRUDA® (pembrolizuma...

Sub-Saharan Africa

View All
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa

By João L. Carapinha

February 12, 2026

Pharmaceutical Tender Investigation Targets Ascendis, Pharma Q, and Sonke The Competition Commission of South Africa has launched a pharmaceutical tender investigation into manufacturers Ascendis, Pharma Q, and...
South Africa Health Reform: Navigating Innovations and Challenges for 2026

By João L. Carapinha

February 10, 2026

South Africa Health Reform: Contrasts in 2026 Public Health Agenda South Africa health reform defines the 2026 public health landscape as a mix of breakthroughs like HIV prevention injections and AI-driven TB diagnos...
Enhancing Patient Safety in Africa’s Healthcare Transformation

By HEOR Staff Writer

February 2, 2026

Prioritizing Patient Safety Africa in 2026 Trends Patient safety Africa stands at the forefront as regulatory bodies drive healthcare self-reliance amid global shifts. A recent article (linked below) outlines five pivotal trends pro...
Navigating Economic Resilience Through Life Sciences Investment

By João L. Carapinha

January 20, 2026

Navigating a Leaderless Global Economy Through Life Sciences Investment In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...